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Tuberculosis is a major cause of morbidity and mortality in women of childbearing age (15–44 years). Despite increased tuberculosis
risk during pregnancy, optimal clinical treatment remains unclear: safety, tolerability, and pharmacokinetic data for many tubercu-
losis drugs are lacking, and trials of promising new tuberculosis drugs exclude pregnant women. To advance inclusion of pregnant
and postpartum women in tuberculosis drug trials, the US National Institutes of Health convened an international expert panel.
Discussions generated consensus statements (>75% agreement among panelists) identifying high-priority research areas during
pregnancy, including: (1) preventing progression of latent tuberculosis infection, especially in women coinfected with human im-
munodeficiency virus; (2) evaluating new agents/regimens for treatment of multidrug-resistant tuberculosis; and (3) evaluating safe-
ty, tolerability and pharmacokinetics of tuberculosis drugs already in use during pregnancy and postpartum. Incorporating pregnant
women into clinical trials would extend evidence-based tuberculosis prevention and treatment standards to this special population.
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Worldwide, approximately 500–800 million women are infect-
ed withMycobacterium tuberculosis, and 3.2 million develop ac-
tive tuberculosis annually, at least 216 000 during pregnancy,
and 480 000 die [1, 2]. Tuberculosis is a leading causes of
death in women of childbearing age (15–44 years), and, if un-
treated, a common cause of nonobstetric maternal mortality [3–
6], pregnancy complications, and infant mortality [4–9].
Women of childbearing age are more likely than men to pro-
gress from latent tuberculosis infection (LTBI) to active tuber-
culosis, possibly owing to immune changes associated with
pregnancy and higher rates of human immunodeficiency
virus (HIV) infection [1, 10, 11]. However, tuberculosis
prevention and treatment during pregnancy poses challenges,
particularly in the setting of HIV coinfection.
Several physiologic adaptations occur throughout pregnancy,
which peak in the third trimester and significantly affect drug
disposition (Supplementary Figure 1) [12, 13]. The safety and
efficacy of individual or multidrug regimens for pregnant women
cannot be predicted without clinical trials, yet safety and pharma-
cokinetic (PK) data during pregnancy are lacking for many tu-
berculosis drugs. Importantly, pregnant women continue to be
excluded from new tuberculosis drug trials, limiting access to
promising new treatment regimens for tuberculosis disease and
infection.
First-line antituberculosis therapy (ATT) for drug-sensitive
tuberculosis is highly effective. However, in absence of well-
controlled studies in pregnant women, first-line tuberculosis
drugs have been listed as US Food and Drug Administration
(FDA) pregnancy category C (ie, no adequate well-controlled
human studies have been performed, but benefits may be accept-
able despite potential risks) (Table 1) [17, 14]. Data regarding
safety, tolerability, and the pharmacokinetics of tuberculosis
drugs during pregnancy have not been collected or reported
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Table 1. Food and Drug Administration Category and World Health Organization Grouping of Drugs Used for Tuberculosis Treatment
Drug Name
FDA
Categorya
WHO
Groupb
Crosses
Placenta (cord:
maternal ratio) Fetal Toxicity
Breastfeeding
Compatible
Teratogenic in
Reproductive
Toxicity Studies
Concerns in Pregnancy and
Postpartum
Isoniazid C 1 Yes CNS defects Yes No Possible hepatotoxicity
Rifampin C 1 Yes Hemorrhage Yes (minimal
passage)
Yesc Possible postpartum hemorrhage;
interacts with NNRTIs, PIs,
decreases efficacy of hormonal
contraceptives
Ethambutol C 1 Yes Jaundice UD (minimal
passage)
Yes (low
incidence)
. . .
Pyrazinamide C 1 UD Jaundice UD (excreted in
breast milk)
UD . . .
Aminoglycosides
Capreomycin C 2 Yes . . . UD Yesd . . .
Streptomycin D 2 Yes Ototoxicity, thrush,
diarrhea
Yes (minimal
passage)
No . . .
Kanamycin D 2 Yes Ototoxicity Yes (minimal
passage)
No . . .
Amikacin D 2 Yes . . . UD UD . . .
Levofloxacin C 3 Yes . . . Yes Noe . . .
Moxifloxacin C 3 Yes . . . UD Noe . . .
Gatifloxacin C 3 UD . . . UD No . . .
Ethionamide/ Prothionamide C 4 UD Developmental
anomalies
UD Yes Developmental abnormalities in
human case series
P-aminosalicylic acid C 4 UD Diarrhea No No . . .
Cycloserine C 4 UD . . . Yes UD Congenital sideroblastic anemia
Terizidone . . . 4 UD . . . UD UD . . .
Thiacetazone . . . 5 UD . . . UD UD . . .
Clofazimine C 5 UD Reversible skin
pigmentation
UD No . . .
Clarithromycin C 5 Yes (0.15) . . . UD Nof . . .
Amoxicillin- clavulanic acid B 5 Yes (0.56) Necrotizing
enterocolitis,
transaminitis
UD No . . .
Linezolid C 5 UD . . . UD No . . .
Imipenem C 5 UD . . . UD No . . .
Rifabutin B . . . UD . . . UD No . . .
High-dose isoniazid C . . . Yes (0.73) CNS Defects UD Nog Possible hepatotoxicity
Bedaquiline B . . . UD . . . UDh No Drug accumulation in tissues
Rifapentine C . . . UD . . . UD Yesi Possible postpartum hemorrhage;
interacts with NNRTIs, PIs, may
decrease efficacy of hormonal oral
contraceptives
Delamanid Not
Approvedj
. . . UD . . . UD Yesj Embryofetal toxicity at maternally
toxic doses in rabbits; breast milk
concentration 4 times higher than
blood in rats
Sources: AAP Statement (2001); Micromedex 2.0; www.fda.gov.
Toxicities known in nonpregnant populations not described in table.
Abbreviations: CNS, central nervous system; FDA, Food and Drug Administration; NNRTIs, nonnucleoside reverse-transcriptase inhibitors; PIs, protease inhibitors; UD, undetermined; WHO,
World Health Organization.
a FDA categories are defined as follows: A, adequate and well-controlled (AWC) studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy; B,
animal reproduction studies have failed to demonstrate a risk to the fetus and there are no AWC studies in humans or animal reproduction studies have shown an adverse effect but AWC studies
in pregnant women have failed to demonstrate a risk to the fetus AND the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; C, animal
reproduction studies have shown an adverse effect on the fetus, there are no AWC studies in humans OR there are no animal reproduction studies and no AWC studies in humans AND
the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; D, there is positive evidence of human fetal risk based on adverse reaction data
from investigational or marketing experience or studies in humans BUT the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; X,
studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing
experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
FDA pregnancy letter categories will be eliminated during the next 3–5 years; instead, explanations concerning potential benefits and risks to the mother, fetus, and breastfeeding child will be
provided based on available data [14].
b WHO tuberculosis drug groups are defined as follows: group 1, first-line agents; group 2, injectables; group 3, fluoroquinolones; group 4, oral bacteriostatic second-line agents; and group 5,
agents with unclear efficacy.
c Teratogenic in rodents given 1–2 times the maximum human dose.
d Teratogenic in rats given 3.5 times the human dose.
e Levofloxacin was not teratogenic in rats at 9.4 times the human dose or rabbits at 1.1 times the human dose. Moxifloxacin was not teratogenic in cynomolgus monkeys at 2.5 times the human
dose, in rats at 0.24 times the human dose, or in rabbits at maximum human doses; rat and rabbit offspring, however, had delayed skeletal development. Temafloxacin, another quinolone,
caused toxic cartilage effects in immature dogs [15].
f Equidoses of the maximum human dose in monkeys resulted in fetal growth retardation at plasma levels double that of human serum levels.
g Based on standard isoniazid dosing.
h Concentrated in rat breast milk.
i Based on studies in rats and rabbits. A small case series in humans (n = 6) showed no evidence of teratogenicity.
j Approved per the European Medicine Agency 2014 European public assessment report on delamanid [16].
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systematically, leading to inconsistencies in national and inter-
national treatment guidelines. The World Health Organization,
for example, recommends the use of pyrazinamide during preg-
nancy in first-line ATT, but the US Centers for Disease Control
and Prevention does not, owing to inadequate data on potential
adverse fetal effects [18–20].
Multidrug-resistant (MDR) tuberculosis presents another
challenge, because treatment options remain extremely limited
during pregnancy. Most aminoglycosides, key in MDR tubercu-
losis treatment, are potentially ototoxic and nephrotoxic for the
fetus [4], and reproductive toxicity studies suggest that other
second-line drugs for MDR tuberculosis, such as ethion-
amide-prothionamide, may have teratogenic potential (Table 1).
Although new compounds are in development and new oral
drugs have been recently approved for MDR tuberculosis treat-
ment in the United States (bedaquiline) and Europe (bedaqui-
line and delamanid), lack of safety or PK data during pregnancy
severely limits their use in this population.
Next, a significant proportion of women who die of tuberculo-
sis during pregnancy and postpartum are coinfected with HIV
[1, 21, 22]. Notably, poor adherence to dual ATT and antiretrovi-
ral (ARV) therapy is problematic in this population [23, 24].
Combination tuberculosis/HIV regimens lead to increased pill
burden, overlapping toxic effects, and drug-drug interactions,
and pregnancy introduces gestational age–dependent changes in
pharmacokinetics and drug tolerability [12, 13]. Rifamycins, for
example, are essential in first-line ATT but alter the metabolism
of ARVs recommended during pregnancy and concentrations of
hormonal contraceptives, significantly complicating family plan-
ning for postpartum women with tuberculosis [25, 26].
Finally, controlling the global tuberculosis epidemic requires
preventing LTBI progression to active disease [27]. The World
Health Organization currently recommends LTBI treatment
among HIV-infected persons residing in high burden settings
and in child contacts of persons with tuberculosis even when
LTBI testing is unavailable [28].Although pregnant women, par-
ticularly if HIV-infected, are at high risk of LTBI progression
[10], the standard regimen (daily isoniazid for ≥6 months) has
never been systematically assessed for safety and PK data in preg-
nancy, though it seems safe in the small numbers studied [29].
Newer, shorter preventive regimens (eg, 12 once-weekly doses
of isoniazid plus rifapentine; 1 month of daily isoniazid plus ri-
fapentine) are now available or under study in nonpregnant pop-
ulations, but pregnant women are excluded from clinical trials of
these regimens [30, 31].
Pregnant women should be allowed to access and benefit
from advances in tuberculosis treatment. Pregnancy provides
an important healthcare system entry point, at which women
can be screened and treated for both tuberculosis and LTBI
[32–35]. Development of evidence-based treatment standards
for pregnant women will require inclusion of this special pop-
ulation into studies of newly approved and investigational drugs
for MDR tuberculosis. Because persons living with HIV are at
highest risk of developing tuberculosis, there is a critical need to
study drug interactions, optimal dosing of ATT, ARVs, and hor-
monal contraception [36, 37] in pregnant and postpartum
women coinfected with HIV and tuberculosis. Studies of ARV
therapy in pregnancy provide a good template for how ATT can
be studied [26].
We present (1) research considerations in pregnant and post-
partum women based on literature review and (2) our consen-
sus statements on 4 key research questions described below. We
also propose clinical research priorities for the prevention and
treatment of tuberculosis in pregnant and postpartum women.
METHODS
Consensus Statement Generation
In May 2013, the National Institutes of Health (NIH) convened
an international expert panel of recognized HIV and tuberculo-
sis clinicians, women’s health researchers, opinion leaders, and
community representatives in Bethesda, Maryland, to partici-
pate in a workshop, “Towards Earlier Involvement of Children
and Pregnant Women in Trials of New TB Drugs.” Panelists
were tasked with generating consensus statements supporting
pathways for accelerated inclusion of pregnant women and chil-
dren (reported separately [38]) in trials of tuberculosis drugs.
Subject matter experts were identified based on review of pub-
lished work; government, regulatory agency, and other partici-
pants were selected based on professional discipline with an aim
to represent key perspectives concerning participation of preg-
nant women in tuberculosis drug trials (eg, legal and regulatory
affairs, medical ethics, reproductive toxicity, and clinicians with
experience in recruiting pregnant women into drug trials).
Discussions were framed by 4 guiding questions developed a
priori by the organizing members (R. S. B., P. J. P.) and listed in
“Results” section. A subgroup of panelists was tasked with con-
ducting a preworkshop literature review (A. G., J. S. M., R. S. B.,
P. J. P., H. S.) that informed draft statements. Draft statements
were then reviewed with panelists via a preworkshop teleconfer-
ence, and subject matter experts addressed the guiding ques-
tions during the in-person workshop. Group consensus
(>75% agreement among panelists) was required for consensus
statement edits; experts from regulatory agencies participated in
discussions as nonvoting panelists. Consensus statements were
subsequently presented at the plenary session for discussion
and finalized where needed via teleconference with all panelists.
Literature Search Strategy
The search strategy used PubMed, Medline, and Embase data-
bases and included articles published in English between 1
January 2001 and 31 March 2013; websites for major regulatory
bodies were searched for most recent versions of relevant guide-
lines/ guidance without date restriction. After the workshop,
all articles published through 15 July 2015, regardless of
VIEWPOINTS • CID 2016:62 (15 March) • 763
publication date and language, were reviewed as retrievable and
translated as needed; any relevant new information was included
in the consensus discussion section. The following search terms
were used: tuberculosis, anti-TB treatment, multidrug-resistant
tuberculosis treatment, multidrug-resistant tuberculosis outcomes,
pregnancy, postpartum, lactation/breastfeeding, pharmacokinetics,
pharmacovigilance, clinical trials, drug development, HIV-infected,
and developmental and reproductive toxicology.
RESULTS
Regulatory and Ethical Considerations for Research During Pregnancy
and Postpartum
Nonclinical Studies
The International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
Use guidance [39], endorsed by the FDA and the European
Medicines Agency, states that nonclinical reproductive toxicity
studies [40] and the standard battery of genotoxicity tests [41]
should be conducted before including pregnant women in any
phase of clinical trials (Supplementary Table and Supplementary
Figure 2).
Clinical Studies
Before including pregnant women in phase II or III clinical
studies, safety data from previous human exposure in nonpreg-
nant individuals are needed [42, 43]. This is also specified in the
Code of Federal Regulations [44], (45CFR46, Subpart B), indi-
cating that “Where scientifically appropriate, preclinical studies,
including studies on pregnant animals, and clinical studies, in-
cluding studies on nonpregnant women, have been conducted
and provide data for assessing potential risks to pregnant
women and fetuses.” These regulations also require that studies
with pregnant women hold out the prospect of direct benefit for
the pregnant woman and/or the fetus, or if there is no prospect
of direct benefit the studies entail no more than minimal risk
and are aimed at developing important biomedical knowledge
which cannot be obtained by other means.
Assessment of minimal risk can be variable and subjective,
and can be particularly challenging in the setting of pregnancy
[45]. Critical consideration of disease severity and treatment
options are essential in the case of pregnant women with tuber-
culosis, particularly MDR tuberculosis. Potential benefit of re-
search on new drugs for MDR tuberculosis in this population
would be significant, and consideration must also be given to
the consequences of off-label use in the absence of evidence-
based guidance. It is safer to administer ATT during pregnancy
in a research setting, given the rigorous safety monitoring, requi-
site informed consent requirements, and ability to confirm cor-
rect dosing [46]. Access to the benefits of research is an essential
component of the ethical principle of justice in clinical research,
and pregnant women have not benefited fairly from research
given their under-representation in past trials [47, 48]. In
November 2013, the FDA issued a draft guidance for pulmonary
tuberculosis drug development, which specifically includes a sec-
tion on drug development in pregnant women [49].
PK Studies
The 2004 US FDA guidance on PK studies in pregnancy recom-
mends that PK studies should be conducted for all drugs already
used during pregnancy that have limited available safety and/or
PK data and all new drugs with anticipated use during pregnan-
cy [50, 51]. Likewise, 2005 European Medicines Agency guide-
lines on drug exposure in pregnancy recommend systematic
collection of information on pregnant women and fetal effects,
particularly in settings where drug therapy is essential for ma-
ternal and/or fetal benefit. Furthermore, the 2008 European
Medicines Agency guidance based contraindications of drug
use during pregnancy on the need for treatment in addition
to relevant nonclinical studies and human experience [52].
Expert Panel Consensus Statements: 4 Guiding Questions
Question 1: When can phase I, II, or III studies be conducted in
pregnant women and women of childbearing potential, and
what data are needed to facilitate their inclusion? Drug develop-
ers should accelerate reproductive toxicity testing, and suppor-
tive incentive measures should be considered. Participation of
pregnant and postpartum women should be encouraged in
phase III trials of drugs that have phase II clinical trial safety
and PK/pharmacodynamic data from nonpregnant women.
Finally, inclusion of pregnant and postpartum women should
be encouraged in clinical trials of any tuberculosis drug likely
to be used during pregnancy and postpartum after approval.
Question 2: Which tuberculosis drugs and populations of
pregnant and postpartum women should be studied? What
are the highest priorities? There is no single ethical principle
to guide prioritization of disease severity versus frequency of
harms. The panel developed and prioritized a list of tuberculosis
drug studies and populations of pregnant and postpartum
women to be studied based on ethical, scientific, and public
health considerations, as follows.
Priority 1: Studies of MDR tuberculosis and LTBI regimens
that address safety, PK data by stage of pregnancy, and drug-
drug interactions with the goal of shortening or simplifying ex-
isting regimens should be prioritized equally in (1) pregnant and
postpartum women with MDR tuberculosis disease (rationale:
MDR tuberculosis has high morbidity and mortality and results
in poor maternal-fetal outcomes) and (2) HIV- infected pregnant
women with LTBI (rationale: immune changes of pregnancy and
HIV infection increase the risk of LTBI progression to tuberculo-
sis; unlike with MDR tuberculosis, 20%–50% of HIV-infected
pregnant women in tuberculosis-endemic countries have LTBI,
and improving LTBI therapy in this population would have a
large public health impact as a prenatal care intervention, reduc-
ing tuberculosis in mothers and young children).
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Priority 2: Opportunistic studies of pregnant or postpartum
women with drug-sensitive tuberculosis receiving a tuberculosis
drug or regimen with limited data in pregnancy or postpartum.
The rationale is that nonpregnant women participating in stud-
ies of investigational tuberculosis drugs may become pregnant
during the study or may receive new and existing drugs in clin-
ical practice. Opportunistic collection of safety and PK data will
help improve tuberculosis management in pregnant and post-
partum women (Table 2) [53, 54].
Priority 3: Women of childbearing potential, including
postpartum women, who take hormonal contraception and
tuberculosis drugs. The rationale is that several hormonal
contraceptives interact with tuberculosis drugs, particularly
rifamycins. Tuberculosis drug trials often require that women
of childbearing potential receive hormonal contraception for
pregnancy prevention. Studies should evaluate the effect of
tuberculosis drugs on concentration and efficacy of hormonal
contraceptives and drug-drug interactions between ARVs,
tuberculosis drugs, and hormonal contraception. To prevent
pregnancies in these studies, nonhormonal contraception (eg,
intrauterine devices and condoms) should be provided along
with hormonal contraception.
Priority 4: Pregnant/postpartum women with tuberculosis
disease or LTBI not meeting the above criteria. The rationale
is that most women with tuberculosis have drug-sensitive tuber-
culosis disease, are HIV uninfected, and are being treated with a
current standard regimen. Studies on the treatment history of
tuberculosis and optimal treatment regimens in these popula-
tions could potentially have a high public health impact.
Question 3: Which candidate drugs/regimens should be pri-
oritized? In accordance with the prioritization of populations
described above, Table 3 displays the panel’s prioritization of
specific tuberculosis drugs/regimens to be studied in pregnant
and postpartum women. All drugs and regimens have been or
are currently being studied in phase IIb or III studies in non-
pregnant populations.
Question 4: What are relevant trial designs to study tubercu-
losis drugs and regimens in pregnant and postpartum women?
PK Studies
PK data generated from nonpregnant trial participants provide
limited information on drug disposition and drug safety in
pregnancy [56, 57]. Based on the 2004 FDA guidance, PK stud-
ies are needed for drugs when, “pregnancy is likely to alter sig-
nificantly the PK of a drug [50].” To characterize the PK of
tuberculosis drugs in pregnancy, the standard approach is to
conduct intensive PK sampling in a small group of women in
a stand-alone trial or in the context of a phase I/II treatment
trial. Typically, intrasubject comparisons of PK parameters dur-
ing pregnancy versus postpartum are made using a classic non-
compartmental analysis approach. In phase III or IV trials or in
clinical settings where pregnant women are already receiving
the drug, investigators can use sparse sampling, generally de-
fined as collecting <3 samples in a dosing interval, coupled
with population PK analyses or opportunistic sampling from
specimens drawn for clinical purposes (Table 2) [58].
Cross-sectional studies can assess PK parameters of interest in
parallel cohorts using the categorical variable of trimester during
pregnancy. Longitudinal studies can incorporate serial assessments
of PK by gestation, parturition, and lactation which allow for
paired analyses and smaller sample sizes. Ultimately, logistical,
statistical and analytical challenges of various trial designs should
focus on informing treatment decisions for pregnant women.
Innovative PK/Pharmacodynamic Modeling to Estimate Target
Doses for Pregnant Women
Sparse sampling strategies coupled with population PK analy-
sis has the following advantages over intensive PK analysis in
a small group of women: (1) reduction in blood sampling for
individual participants; (2) improved ability to characterize
variability in drug pharmacokinetics, including the effects of
important covariates (eg, age, weight, race, HIV status, phar-
macogenetics, and companion drugs) on PK parameters; and
Table 2. Characteristics of Optimal Versus Minimal Opportunistic
Approaches to Pharmacokinetic Sampling for the Study of Tuberculosis
Drugs During Pregnancya
Key
Characteristic Optimal Approach Minimal Approach
No. of
samples
3–7 1–7
Timing of
samples
Determined before study
begins based on how many
samples can be collected
within dosing interval
Late in dosing interval
(trough samples are most
informative)
Timing in
pregnancy
Several time points (2nd and 3rd
trimester and postpartum)
3rd trimester better than 2nd
trimester better than post
partum
No. of
womenb
>20 for rich or semi-intensive
design; >40 for sparse
design
>10 for rich or semi-
intensive design; >20 for
sparse design
Data to be
collected
Dosing time (including previous
doses), week of pregnancy,
weight and other clinical/
demographic variables
Dosing time (including
previous doses), week of
pregnancy, and weight
Analysis
method
Population and/or PK modeling Population and/or
conventional PK modeling
Abbreviation: PK, pharmacokinetic.
a Opportunistic collection of safety and PK data fromwomen at different stages of pregnancy
who are receiving drug(s) of interest as part of clinical care may improve the understanding
and management of tuberculosis and human immunodeficiency virus treatment in pregnant
and postpartum women. Although such studies can efficiently provide critical PK data,
clinical outcome data may be biased since enrollment is limited to subjects who tolerate
and have an adequate clinical response to the drug(s) being studied. Examples of such
approaches are employed in International Maternal Pediatric Adolescent AIDS Clinical
Trials Network (IMPAACT) studies P1026s, P1078, and P2001 (Table 5) and have also
been used to assess rifampin, isoniazid, and efavirenz concentrations and interactions.
In general, opportunistic PK sampling should involve the collection of as many samples as
possible in a dosing interval (maximum of 5–7 samples spread equally in a dosing interval),
but even a single sample can be useful if that is all that is feasible. If it is known ahead of time
that opportunistic design is possible, relevant optimal sampling time windows can be
determined. Dosing times must be recorded correctly, and pregnancy-related variables
must be collected. In general, the more participants enrolled the better, but usually any
design including >20 women is informative.
b Rich, semi-intensive, and sparse designs are defined as >5, 3–5, and <3 samples in a
dosing interval, respectively.
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(3) more power to characterize longitudinal changes in drug
disposition. Mathematical modeling using PK data from
pregnant women and PK or outcomes data from nonpregnant
adults can be used to predict appropriate doses in pregnant
women at different stages in pregnancy. Furthermore, popula-
tion PK modeling can describe drug distribution in breast milk
and in newborns. Physiologically based PK modeling can help
predict exposures during pregnancy but is limited by current
knowledge of the structural and functional changes occurring
in the primary organs of drug disposition at different gesta-
tional stages [52, 57].
Safety Monitoring and Pharmacovigilance
Clinical trials of tuberculosis drugs in pregnant women should
include close maternal and fetal monitoring with clearly defined
safety stopping rules and safety monitoring committee over-
sight. If a woman becomes pregnant during a trial, the tubercu-
losis drug’s preclinical development toxicity profile, availability
of alternative treatment regimens, and stage of pregnancy
should determine whether trial continuation is offered. For
women who continue in a trial, an additional informed consent
process should be implemented that includes risks of untreated
maternal disease, risks and benefits of the study agent, alternative
treatment options, and embryofetal toxicity counseling. At
minimum, data should be collected on pregnancy outcomes
and the health of the mother and child (pregnancy registry use
is encouraged). Data should include (1) pregnancy outcome,
Table 3. Summary of Proposed Research Priorities for Tuberculosis Drugs in Pregnant and Postpartum Women
Drug
Research
Prioritya Conditions to be Studied Rationale for Priority
Moxifloxacin/
levofloxacin
First tier MDR tuberculosis (including isoniazid
monoresistance); MDR tuberculosis
exposure and LTBI; drug-sensitive
tuberculosis (treatment shortening)
Important in MDR tuberculosis regimens; widely available; reasonable safety data
in pregnancy [18, 55]
Disadvantage: Concern for fetal musculoskeletal deformities
Isoniazid/
rifapentine
First tier LTBI Large public health benefit in tuberculosis prevention; effective in nonpregnant and
HIV-infected adults; pregnant/postpartum women have increased risk of
tuberculosis; women preferentially access healthcare during pregnancy; poor
completion rates with current longer regimen; correct dosing in pregnancy not
established
High-dose
isoniazid
First tier MDR tuberculosis Widely available and reasonable safety in pregnancy at standard doses
Disadvantage: Potential for increased hepatotoxicity in pregnancy
Pyrazinamide Second tier Drug-sensitive tuberculosis Discrepancy between WHO and CDC recommendations on use in pregnancy;
enables shortening of first-line ATT from 9 to 6 mo, a benefit currently not
extended to pregnant women in the United States; important in MDR
tuberculosis regimens
Clofazimine Second tier MDR tuberculosis; pre-XDR
tuberculosis; XDR tuberculosis
Long history of use in leprosy and now some use in MDR tuberculosis in
pregnancy; standard of care in pre-XDR and XDR tuberculosis; alternative to
injectables in pregnancy
Disadvantages: Skin discoloration (reversible); limited tuberculosis data in
nonpregnant adults
Bedaquiline Second tier MDR tuberculosis FDA category B; important in MDR tuberculosis regimens
Disadvantages: Limited clinical experience; long half-life and potential for drug
accumulation in tissues; boxed warning for cardiac arrhythmias
Delamanid Second tier MDR tuberculosis Important in MDR tuberculosis regimens; more favorable adverse effect profile
Disadvantages: Not FDA approved; can cause QT prolongation; limited clinical
experience
Linezolid Second tier M/XDR tuberculosis Benefit in M/XDR tuberculosis treatment
Disadvantages: Adverse effects include myelosuppression, peripheral neuropathy,
thrombocytopenia, and optic neuritis
Abbreviations: ATT, antituberculosis therapy; CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administration; HIV, human immunodeficiency virus; LTBI, latent
tuberculosis infection; MDR, multidrug resistant; WHO, World Health Organization; XDR, extremely drug resistant.
a Proposed research priority classification for tuberculosis drugs used during pregnancy or postpartum, defined as follows: first tier: highest priority drugs/regimens for MDR tuberculosis and
HIV-infected LTBI/tuberculosis exposure; second tier: high-priority drugs for drug-sensitive tuberculosis, MDR tuberculosis, and XDR tuberculosis.
Table 4. Summary of Consensus Statements
Pregnant and postpartum women should be eligible for all phase III trials
designed for treatment of MDR tuberculosis unless there is a compelling
reason for exclusion; aminoglycoside drugs, for example, should be
excluded during pregnancy because of their teratogenic potential, but this
should not preclude evaluation of other promising new agents.
Drug companies developing new tuberculosis drugs should be encouraged
to complete reproductive toxicity studies early in drug development,
before beginning phase III trials; these data are needed to adequately
inform decisions about the inclusion of pregnant women in subsequent
clinical trials.
Specific trials of shortened treatment regimens for LTBI should be designed
for pregnant women to facilitate treatment completion of regimens and
reduce the risk of progression to tuberculosis disease during the high-risk
pregnancy/postpartum period.
Targeted PK studies in pregnant and postpartum women should be nested
into all trials to provide data on appropriate dosing of drugs during
pregnancy and postpartum, when evidence-based dosing guidelines are
not already available and particularly when pregnancy is likely to have a
significant impact on drug disposition.
A registry should be established to accumulate data on the outcomes of
pregnancies exposed to any tuberculosis drugs to allow monitoring of
adverse events and to provide data to inform inclusion of pregnant
women in clinical trials.
Abbreviations: LTBI, latent tuberculosis infection; MDR, multi-drug resistant; PK,
pharmacokinetic.
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including live births, stillbirth, miscarriage, and pregnancy termi-
nations; (2) small size for gestational age and low birth weight
(<2500 g); (3) preterm birth; (4) congenital malformations; and
(5) maternal and infant morbidity and mortality rates.
Pregnancy Registries
Evaluation of the risk of a particular drug exposure in pregnan-
cy is commonly based on data collection from post-approval
observational studies; drug data regarding potential teratogenic-
ity usually is limited to nonclinical animal data. Pregnancy expo-
sure registries are prospective, observational studies that monitor
for evidence of teratogenicity and safety of medication. Well-
designed registries offer advantages over spontaneous, nonsys-
tematic adverse event reporting by clinicians [59]. Regulatory
guidance documents address study design, monitoring, evalua-
tion, and data interpretation [17, 55, 59, 60].
DISCUSSION
A summary of the consensus statements and priorities is shown
in Table 4. Despite substantial tuberculosis-related morbidity
and mortality in pregnant/postpartum women and their in-
fants, drug-sensitive tuberculosis, MDR tuberculosis and LTBI
care is currently being provided without sufficient clinical trial
data on drug safety and dosing. Studies in pregnant or postpar-
tum women with tuberculosis are needed to provide accurate
data to improve clinical treatment decisions. Engagement of
trial sponsors, pharmaceutical companies, regulatory authori-
ties, and health systems, including those in countries most
affected by tuberculosis, are needed to support a pathway for ac-
celerated inclusion of pregnant and postpartum women in trials
of tuberculosis drugs. Clinical trials should reflect the public
health priorities of the sites where they are conducted and
occur in settings where similar trials are already being conduct-
ed in nonpregnant adults. Ideally, a plan for making new drugs
available (ie, post-trial access) at the local level should be ob-
tained before clinical trials commence. Establishing high-qual-
ity evidence demonstrating the efficacy and safety of new drugs
can lead to advocacy in favor of rapid availability. Importantly, a
mindset of presumed inclusion of pregnant and postpartum
women into trials of promising tuberculosis agents should be
adopted, as is already the case for pregnant women with HIV
infection, who have significantly benefited from early inclusion
in clinical trials. Involvement of local site investigators and
community advisory boards and adequate support and over-
sight of trial conduct is critical to the process [61, 62].
Since this workshop, investigators have made some progress
in initiating new studies and modifying existing studies to help
fill the data void for tuberculosis management in pregnancy
(Table 5). A working group has been established to develop a
pregnancy registry for tuberculosis drug studies. Only through
responsible inclusion of pregnant and postpartum women in
tuberculosis trials will we be able to provide clinicians and pol-
icy makers with the evidence needed to optimize their care
globally.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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Table 5. Ongoing and Planned Clinical Trials in Pregnant Women (Current as of October 2015)
Study Regimen Status Study Population Sponsor
Prevention
IMPAACT P1078
NCT01494038
Evaluating the safety of immediate vs
deferred isoniazid preventive therapy
among HIV-infected pregnant women
Enrolling (results
expected in 2017)
HIV-positive pregnant women without active
tuberculosis in settings with a high
tuberculosis burden (Haiti, India, sub-Saharan
Africa, Thailand)
NIH, IMPAACT
IMPAACT P2001a PK, tolerability, and safety of once-weekly
rifapentine and isoniazid in HIV-infected
and HIV-uninfected pregnant and
postpartum women with latent
tuberculosis infection
In development Pregnant women (HIV positive and HIV
negative) with latent tuberculosis infection or
known recent exposure to pulmonary
tuberculosis
NIH, IMPAACT
IMPAACT/ACTG
PHOENIxa
Evaluating efficacy of delamanid vs isonaizid
for HIV-infected and uninfected persons
exposed to MDR tuberculosis
In development Children and adult household contacts of
patients with MDR tuberculosis, with
possible inclusion of postpartum women
NIH, IMPAACT,
ACTG
Treatment
IMPAACT P1026s
NCT00042289
PK study of antiretroviral drugs and related
drugs during and after pregnancy
Enrolling (results
expected 2016); in
development
HIV-infected and uninfected pregnant and
postpartum women on first-line tuberculosis
treatment; HIV-infected and uninfected
pregnant and postpartum women receiving
treatment for MDR tuberculosis
NIH, IMPAACT
Abbreviations: ACTG, AIDS Clinical Trials Group; HIV, human immunodeficiency virus; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trials Network; MDR, multidrug
resistant; NIH, National Institutes of Health; PHOENIx, Protecting Households On Exposure to Newly Diagnosed Index; PK, pharmacokinetic.
a Data from the IMPAACT Web site [63].
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